Abstract: Active ingredient-containing layered articles or discs which are suitable, in particular, as active ingredient reservoirs for transdermal therapeutic systems are obtained starting from an elongate article having an enveloping surface corresponding to the contour of the layered articles to be produced, and having a cross-sectional constitution corresponding to the internal structure of the layered articles, by layered detachment perpendicular to the axial direction of the elongate article. In the simplest case, this article consists of a uniform active ingredient-containing composition and forms a solid cylinder which is converted into single products perpendicular to the axis with identical spacing to result in circular one-compartment discs identical to one another.

Abstract: The present invention relates to morphine and diamorphine salts of anionic non-narcotic analgesics belonging to the type of substituted carboxylic acids, preferably the morphine and diamorphine salts of diclofenac (Formula 1); to processes for their production, the use of these salts in the treatment of diseases, as well as to pharmaceutical preparations comprising these salts.

Abstract: A volume-expandable, sheet-like application form suitable as an active substance carrier, in particular for oral application, in the form of a film comprising a mixture of fillers, cleansers, cosmetics, or active substances, film formers, and softeners has portions of a highly absorbent hydrogel former which swells on contact with water and assumes several times its original volume.

Abstract: A method for the application of an active substance patch for controlling or alleviating an addiction such as drug addiction, addiction to pills or analgesia is characterized in that two or more active substance patches are applied simultaneously, sequentially or alternately within a given therapy plan under surveillance of the blood level of the active substance in a way that allows the achievement of an active substance blood level which is high enough for a successful suppression of the addiction and remains constantly effective throughout a useful period of administration.

Abstract: An active-substance-containing transdermal therapeutic system for the controlled release of estradiol or its pharmaceutically acceptable derivatives alone or combined with gestagens consisting of a backing layer, an active-substance-containing reservoir which is bonded thereto and produced by using pressure sensitive adhesives, and a removable protective layer is characterized by the fact that the pressure sensitive adhesive comprises esters of colophony.

Abstract: A therapeutic system for supplying active substances to the skin consists of a backing layer remote from the skin, with at least one active substance depot. The depot may consist of a fluid active substance or a fluid composition comprising an active substance delivery control matrix. There is also included an adhesive fixing device for fixing the therapeutic system on the skin. The therapeutic system is characterized in that the active substance depots (14) consist of at least one adjuvant having a supporting and distributing function by being provided with a planar textile material completely surrounded by matrix (12).

Abstract: A therapeutic system for supplying active substances to the skin consists of a backing layer remote from the skin, with at least one active substance depot. The depot may consist of a fluid active substance or a fluid composition comprising an active substance delivery control matrix. There is also included an adhesive fixing device for fixing the therapeutic system on the skin. The therapeutic system is characterized in that the active substance depots (14) consist of at least one adjuvant having a supporting and distributing function by being provided with a planar textile material completely surrounded by matrix (12).

Abstract: A therapeutic system for supplying active substances to the skin consists of a backing layer remote from the skin, with at least one active substance depot. The depot may consist of a fluid active substance or a fluid composition comprising an active substance delivery control matrix. There is also included an adhesive fixing device for fixing the therapeutic system on the skin. The therapeutic system is characterized in that the active substance depots (14) consist of at least one adjuvant having a supporting and distributing function by being provided with a planar textile material completely surrounded by matrix (12).

Abstract: A pharmaceutical form for delivery of active substances to wounds is characterized in that this is designed to be coherent, sheet-like and, in its extent in terms of area, equal to or smaller than the wound area to be managed, and contains active substance in a defined amount in homogeneously dispersed form.

Abstract: A pharmaceutical formulation for the prophylaxis and preliminary treatment of a poisoning caused by organophosphorus cholinesterase inhibitors is characterized in that it consists of an active substance combination of at least one parasympathomimetic and at least one parasympatholytic.

Abstract: A therapeutic system for supplying active substances to the skin consists of a backing layer remote from the skin, with at least one active substance depot. The depot may consist of a fluid active substance or a fluid composition comprising an active substance delivery control matrix. There is also included an adhesive fixing device for fixing the therapeutic system on the skin. The therapeutic system is characterized in that the active substance depots (14) consist of at least one adjuvant having a supporting and distributing function by being provided with a planar textile material completely surrounded by matrix (12).

Abstract: A sprayable, film-forming active substance preparation for the application to plants is characterized by the fact that films which can be produced thereof are pressure-sensitive adhesive, water-insoluble, and at least partially biodegradable.

Abstract: A process for the administration of a flowable solid, semisolid, or liquid medium exhibiting a controlled release of at least one active substance to plants by means of injection using needle-free, pressure-actuated devices is characterized in that the medium comprises active substance-containing microparticles of a maximum size of 100 .mu.m including the following components:a) 0.5-70%-wt. of at least one active substance,b) 10-70%-wt. of at least one biodegradable polymer,c) up to 20%-wt. of formulation adjuvants.

Abstract: An active substance-containing patch for the controlled release of estradiol or its pharmaceutically acceptable derivatives alone or in combination with gestagens from a backing layer, an active substance-containing reservoir connected thereto and produced by using pressure sensitive adhesives and at least one penetration enhancer, and a removable protective layer is characterized by the fact that the penetration enhancer is selected from substances based on carboxylic acids.

Abstract: A layered tablet for the controlled release of active substances in a liquid medium comprising at least one active substance-containing, layered matrix with contact surfaces to the liquid medium which are at least partially provided with a cover layer delaying or preventing the active substance release, is characterized by the fact that the cover layer is at least one additional layer lying with thickness gradients on contact surfaces of the layered, prefabricated matrix, or that the matrix is at least one additional layer lying with thickness gradients on contact surfaces of the layered, prefabricated cover layer, which additional layer is applied by pressing powdery or granular material on the layered, prefabricated matrix or on the layered, prefabricated cover layer.

Abstract: The invention refers to a transdermal therapeutic system for the delivery of active agents to the human body.The backing layer consists of common pharmaceutical plastic layer laminates which require labeling, e.g. by printing. The problem to solve lies in toxicological, technological and drug law disadvantages of pigment- or varnish-printing.According to the invention, the coding does not consist of an ink- or pigment layer but in an effect on surface properties of the backing layer corresponding to the coding.

Abstract: A transdermal therapeutic system having a layered structure, comprising a backing layer (1) and at least one active substance-containing matrix layer (2), for storage purposes being placed onto a removable protective layer (4) coated with an abherent (3) is characterized in that said abherent (3) has a lower diffusion coefficient for the active substance used than the base materials used in the matrix layer (2) or in the matrix layers.

Abstract: A process for the continuous production of transdermal therapeutic patches, wherein a laminate of an auxiliary layer (3) siliconized at least on one side, an active substance-containing, pressure-sensitive adhesive layer (4), and a supporting layer (9) is prepared as a strip-shaped web (1) first, and the active substance-containing sections (4') obtained by punching said layers (3) and (4) across the web direction are intermittently transferred onto a second web (2), the punching procedure taking place in the rest phase between the cycles and the transfer procedure onto the second web (2) being carried out preferably at equal distances by means of a transfer device (11, 12), is characterized by the fact that the supporting layer (9) is stripped from the active substance-containing sections (4') during the transfer first, and that then the sections (3') of the auxiliary layer are removed with the aid of a process layer (5) which has been rendered pressure-sensitive adhesive.

Abstract: A childproof package for active substance patches is formed as primary package and comprises at least one mechanically tough, in particular tear-resistant layer.

Abstract: This invention relates to a process for the production of a transdermal therapeutic system containing the active substance 17-.beta.-estradiol and optionally further active substances having a laminated structure positioned on a backing layer which is essentially impermeable to active substance and moisture, one or more matrix layers and optionally an adhesive layer, characterized in that at least one of the matrix layers or the adhesive layer contains anhydrous 17-.beta.-estradiol in crystalline form.